TRP Versus Photo Selective Vaporization for Obstructive Benign Prostatic Hyperplasia Management

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare medical efficacy and cost effectiveness of two surgical options for obstructive BPH management : transurethral resection of the prostate with photo selective vaporization of the prostate using the high powered 532nm laser.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP

NCT04398420

Benign Prostatic Hypertrophy

TERMINATED NA

Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP)

NCT03062111

Benign Prostatic Hyperplasia

TERMINATED NA

Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate

NCT01073241

Benign Prostatic Hyperplasia

UNKNOWN NA

To Compare Outcomes After Transurethral Enucleation of Prostate Versus Transurethral Resection of Prostate

NCT01958892

Benign Prostatic Hyperplasia

COMPLETED

Impact of Bladder Underactivity on Treatment Outcomes of Laser Prostatectomy

NCT02243540

Prostatic Hyperplasia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to compare medical efficacy and cost effectiveness of two surgical options for obstructive BPH management : transurethral resection of the prostate with photo selective vaporization of the prostate using the high powered 532nm laser. Patients were randomized in two groups after inclusion. Perioperative data were collected, and follow-up was conducted for one month.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 : TURP

Surgery: TransUrethral Resection of the Prostate

Group Type OTHER

TURP

Intervention Type PROCEDURE

TransUrethral Resection of the Prostate

2 : PVP

Surgery: Photo selective Vaporization of the Prostate

Group Type OTHER

PVP

Intervention Type PROCEDURE

Photo selective Vaporization of the Prostate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TURP

TransUrethral Resection of the Prostate

Intervention Type PROCEDURE

PVP

Photo selective Vaporization of the Prostate

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male, 50 years of age or older.
2. American Society of Anesthesiology (ASA) classification of physical status, class 1-3
3. Signed an informed consent at the beginning of the study.
4. Patients presenting with LUTS associated to benign prostatic enlargement for more than 3 months, needing a surgical management, with at least one of the following situations: disability score ≥3, I-PSS ≥12, or full urinary retention
5. Qmax ≤12ml /s for no drained patients with voided volume\> 125 ml.
6. Estimated prostate weight between 25g and 80g
7. Patient free of catheter with PVR ≤ 300cc
8. Patient without renal disorders.
9. No prostate cancer suspicion at clinical examination, including DRE.
10. PSA ≤ 10 ng/ml, with negative prostate biopsies of PSA is between 4 and 10 ng/mL if patient is 75 years or younger or has a life expectancy of more than 10 years.
11. In case of anticoagulation or anti-aggregation therapy, necessary preoperative visit by anaesthesiologist to determine the supply therapy around surgery.
12. In case of current BPH medical management, alpha blockers and herbal medicines should be stopped one week before surgery and 5-alpha-reductase-inhibitors should be stopped one month before surgery.
13. Patient must be affiliated to the French social healthcare or equivalent

Exclusion Criteria

1. Uncontrolled cardiopulmonary disorder, previously or recently diagnosed by standard methods
2. Assessed sphincter detrusor dyssynergia, or myasthenia, multiple sclerosis, or Parkinson disease.
3. History of pelvic lesions with abdominal sphincter injury.
4. Urinary tract infection without antibiotics.
5. Patient with urinary catheter or suprapubic catheter because of an acute urinary retention linked to an alternative diagnosis or impaired bladder sensation.
6. Subject with neurogenic bladder and/or sphincter abnormalities
7. Subject with confirmed or suspected malignancy of the prostate or the bladder.
8. Previous prostatic surgery.
9. History of bladder stone, major hematuria, urethral stricture, bladder neck stenosis.
10. Patient having a prosthesis in the procedure area
11. Patient with an active anorectal disease
12. Treatment emergency
13. Individual unable to respect timing and visits determined by the protocol.
14. Constitutional hemostasis and coagulation abnormalities not linked to oral medications
15. Any disease or patient condition which can be a contra indication to his enrolment in the study, according to the investigator.

Minimum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No